nintedanib + docetaxel + prednisone

Nintedanib + docetaxel + prednisone is a three-drug combination therapy investigated and used primarily for advanced non-small cell lung cancer (NSCLC). This regimen combines: - **Nintedanib**, a small molecule multi-targeted tyrosine kinase inhibitor that interferes with the VEGFR 1–3, FGFR 1–3, and PDGFR α/β signaling pathways, blocking tumor angiogenesis and growth[4]. - **Docetaxel**, a cytotoxic chemotherapeutic agent (taxane class) that stabilizes microtubules, inhibiting cell division and inducing apoptosis[3]. - **Prednisone**, a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive effects, often used to mitigate chemotherapy side effects. The combination of nintedanib and docetaxel has shown favorable efficacy in improving progression-free and overall survival in second-line treatment settings for advanced NSCLC, especially adenocarcinoma, compared to docetaxel monotherapy[1][3][4][5]. Prednisone is commonly added to chemotherapy regimens to reduce inflammation and treatment-related adverse effects.